A Phase 3 interventional study of Dronabinol and Placebo in Central Neuropathic Pain in Multiple Sclerosis, sponsored by Bionorica Research GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Bionorica Research GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Multiple Sclerosis with a site in Germany — 27 open to participants now, 49 under way, 15 of them phase 3. Multiple Sclerosis · Germany.
Among the 252 studies in Multiple Sclerosis with a site in Germany, this one is the 99th largest by enrollment of the 190 interventional ones that give a count, is one of 19 that started in 2007, is one of 78 in phase 3, and was the 60th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →27 of the 252 studies in Multiple Sclerosis with a site in Germany are open now. Recruiting first, the newest first:
Miltenyi Biomedicine GmbH · Sites in Germany
Ages 18–55
Charite University, Berlin, Germany · Sites in Germany
Ages 18–70
AstraZeneca · Sites in Germany, United States, Australia and 2 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 33 more countries
Ages 18–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–60 · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 54 · Phase 3 80 · Phase 4 23
First in 2002; this study’s year is marked. 19 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 258 across the 190 interventional studies, 304 across the 62 observational. Of the 192 that completed or were terminated, 97 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 252 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bionorica Research GmbH as lead sponsor.
Bionorica Research GmbH has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Multiple Sclerosis with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07183683Charite University, Berlin, GermanyStimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction | 2026-12-30 |
| NCT06280755icometrixClinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. | 2027-04 |
| NCT06782490CelgeneA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | 2027-05-26 |
Add all 11 to your calendar (.ics) → With an account.
Among the 252 studies in Multiple Sclerosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.
Multiple sclerosis (MS) is in all probability an autoimmune disease causing severe neurological disability due to inflammation and degeneration in the central nervous system (CNS). MS affects over 1 million people worldwide. Central neuropathic pain is associated with approximately 30% of all patients with MS. MS-accompanying pain has a major impact on the patients' quality of life as usual conventional analgesics are little effective. The aim of this clinical study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Dronabinol
Drug: Placebo
oral solution, daily dose up to 15 mg, treatment up to 2.5 years
Also known as: (-)trans-delta9-tetrahydrocannabinol
oral solution
Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary
Time frame: max. 2.5 years
Likert Numerical Rating Scale pain relief
Time frame: max. 2.5 years
Pain-related sleep interference
Time frame: max. 2.5 years
SF-36 (QoL-questionnaire)
Time frame: max. 2.5 years
Intake of rescue medication
Time frame: 48 weeks
The record gives a start of Jun 2007, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol